Business Overview: Grace Therapeutics, Inc. (NASDAQ: GRCE)

---

Executive Summary

Grace Therapeutics (formerly Acasti Pharma) is a clinical-stage biopharmaceutical company focused on reformulating already-approved drug compounds for rare and orphan diseases using the FDA's Section 505(b)(2) regulatory pathway, which allows a company to rely in part on existing safety and efficacy data for the underlying active ingredient rather than starting entirely from scratch. All three of its current pipeline candidates carry orphan drug designation.

The company's lead and by far most advanced candidate, GTx-104 — an injectable nimodipine formulation for intravenous infusion in aneurysmal subarachnoid hemorrhage (aSAH) — completed a Phase 3 safety trial (STRIVE-ON) and had a New Drug Application accepted by the FDA in August 2025 with an April 23, 2026 PDUFA target date. In April 2026, however, the FDA issued a Complete Response Letter (CRL), declining to approve GTx-104 and citing chemistry, manufacturing, and controls (CMC) issues, non-clinical toxicology risk-assessment gaps, and cGMP deficiencies at the company's contract manufacturer — not safety or efficacy concerns with the drug itself. As of March 31, 2026, the company had $17.0 million in cash and cash equivalents, which it says provides at least 12 months of runway, and reported a fiscal 2026 net loss of $7.8 million, an improvement of $1.8 million from the prior year.

---

1. Core Business Model & How They Work

Approved Active Ingredient ➡️ Novel Reformulation ➡️ 505(b)(2) NDA Pathway
 (e.g., nimodipine,              (new delivery route,      (leverages existing
  betamethasone,                  dosage form, or           safety/efficacy data
  bupivacaine)                    administration method)     for the underlying
                                         |                    compound)
                                         ▼
                              Orphan Drug Designation
                              (rare/orphan disease focus)
                                         |
                                         ▼
                      FDA Review ➡️ (if approved) Hospital-Based
                                     U.S. Sales Force / Ex-U.S.
                                     Partnering, or Out-License/
                                     Sell Non-Lead Assets

Grace Therapeutics has no manufacturing facilities of its own and relies entirely on third-party contract manufacturers to produce clinical and (eventually) commercial supply — a structural dependency that became directly relevant when the FDA's April 2026 CRL for GTx-104 cited cGMP deficiencies specifically at the company's contract manufacturer rather than at Grace Therapeutics itself.

---

2. Product Portfolio

---

3. Competitive Landscape

Grace Therapeutics' core competitive strategy is to use the 505(b)(2) pathway to target rare and orphan conditions — by definition, markets too small to attract the largest pharmaceutical companies' primary R&D investment, but potentially large enough to support a focused specialty biopharma. This is a "compete by not competing head-on" strategy: rather than developing a novel molecule against established large-market drugs, Grace Therapeutics reformulates known-safe compounds for conditions with few or no approved alternatives (aSAH management, A-T, PHN).

The clearest current competitive reality, however, is regulatory rather than commercial: GTx-104's path to market now depends on resolving the FDA's CMC, non-clinical, and manufacturing-quality concerns before it can compete against the existing standard of care (oral nimodipine capsules) at all.

---

4. Strategic Strengths & Risks

Strengths

• Orphan drug designations across all three pipeline candidates provide regulatory incentives (market exclusivity periods, if approved) and target genuinely underserved patient populations.
• Phase 3 clinical data already in hand for GTx-104, with the CRL explicitly not citing safety or efficacy problems — meaning the core clinical case for the drug remains intact even though the submission itself was rejected on manufacturing/CMC grounds.
• Narrowing net losses ($7.8 million in fiscal 2026, down $1.8 million year-over-year) and a stated 12-month cash runway as of March 31, 2026.
• Portfolio discipline. Deprioritizing GTx-102 and GTx-101 concentrates resources on the most advanced, highest-probability asset (GTx-104) rather than spreading limited cash across three programs.

Risks

• GTx-104's regulatory setback is the central risk to the entire company. The CRL means commercial launch, and the revenue it would generate, is delayed by at least the time needed to resolve CMC and contract-manufacturer cGMP deficiencies and complete a resubmission cycle — with no guarantee of ultimate approval.
• Reliance on third-party contract manufacturing, which the CRL itself shows can become a single point of failure for the entire regulatory timeline.
• Two of three pipeline assets are being impaired and deprioritized (GTx-102, GTx-101), narrowing the company to effectively a single-asset bet on GTx-104.
• Limited cash runway. $17.0 million in cash against a stated 12-month runway means the company will likely need additional financing, especially given the GTx-104 delay, which could be dilutive.

---

5. Financial Overview

---

6. Summary Conclusion

Grace Therapeutics is, at its core, a single-asset bet dressed as a three-candidate pipeline: GTx-102 and GTx-101 are being impaired and deprioritized, leaving GTx-104 — a clinically-validated but now regulatorily-delayed reformulation of nimodipine for aSAH — as the company's entire near-term value driver. The April 2026 Complete Response Letter is a serious but not fatal setback, since the FDA's stated concerns were manufacturing and CMC-related rather than about the drug's safety or efficacy; the company's fate now hinges on how quickly and credibly it can resolve those contract-manufacturer issues through its scheduled Type A meeting and a subsequent resubmission, against a finite cash runway that will likely require additional financing before any resolution is reached.